Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases

• 收藏
• 分享

专利权人:

Inc.;Delinia

发明人:

Jeffrey Greve

申请号：

US16352003

公开号：

US10774126B2

申请日:

2019.03.13

申请国别(地区):

US

年份:

2020

代理人:

摘要：

This invention provides for a fusion protein between an IL2αβγ Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2αβγ form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/